ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar


No votes yet
 
Related
0 min
25/09/2020
ROVI obtains second place in a global sustainability rating
ROVI participated voluntarily in this rating, which measures the sustainability of companies based on criteria such as corporate governance...
1 min
25/09/2020